Name change reflects Company’s evolution, renewed team and strategic focus on advancing its lead compound into human trials Company to trade under ticker SKYE effective January 19, 2021 Name change reflects Company’s evolution, renewed team and strategic focus on advancing its lead compound into human trials Company to trade under ticker SKYE effective January 19, 2021
More:
Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience
Related Post
- Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease - March 7th, 2021
- Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021 - March 7th, 2021
- Orion Corporation: Managers’ transactions – Jukka Ylppö - March 7th, 2021
- Transparency Notification - March 7th, 2021
- Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International Symposium 2021 - March 7th, 2021
- Agile Therapeutics to Present at Upcoming March Investor Conferences - March 7th, 2021
- Tauriga Sciences Inc. Selects First Foods Group, Inc. to Manufacture its New, Full Spectrum CBD Infused Product Line - March 7th, 2021
- Imara Reports Full Year 2020 Financial Results and Business Highlights - March 7th, 2021
- Aquestive Therapeutics to Host Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event on March 25 at 9:00 a.m. ET - March 7th, 2021
- DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference - March 7th, 2021
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 7th, 2021
- Lowell Farms Inc. Emerges From Acquisition With an Eye Toward Dominance in California’s Cannabis Industry and Beyond - March 7th, 2021
- Psyence Group Announces Partnership With Base Pair Health and Strengthens Management Team - March 7th, 2021
- AnPac Bio Regains Compliance with Nasdaq Continued Listing Requirement - March 7th, 2021
- Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections - March 7th, 2021
- Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection - March 7th, 2021
- Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021 - March 7th, 2021
- Immutep Expands Part B of TACTI-002 Study - March 5th, 2021
- Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial - March 5th, 2021
- Fulgent Genetics to Participate in the Oppenheimer 31st Annual Healthcare Conference - March 5th, 2021
- Longeveron Expands Enrollment Criteria for its Phase 1 RECOVER Trial Evaluating Lomecel-B Infusion to Treat Acute Respiratory Distress Syndrome due to... - March 5th, 2021
- Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences - March 5th, 2021
- Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat... - March 5th, 2021
- Brickell Biotech To Host Key Opinion Leader Webinar on the Hyperhidrosis Market - March 5th, 2021
- Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2nd... - March 5th, 2021
- Novan to Present at the H.C. Wainwright Global Life Sciences Conference - March 5th, 2021
- MediPharm Labs Closes Previously Announced Bought Deal Equity Financing - March 5th, 2021
- Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced... - March 5th, 2021
- Timber Pharmaceuticals Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference - March 5th, 2021
- Number of voting rights as of March 5, 2021 - March 5th, 2021
- Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma’s Phase 2 Clinical Trial of Brilacidin for COVID-19 - March 5th, 2021
- Bavarian Nordic to Host Full Year 2020 Results Conference Call - March 5th, 2021
- 22nd Century Group to Participate in Investor Conferences in March 2021 - March 5th, 2021
- Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference - March 5th, 2021
- Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2021 - March 5th, 2021
- Nicox: 2021 Extraordinary and Ordinary Shareholder Meetings - March 5th, 2021
- Vor Biopharma to Present at the Barclays Global Healthcare Conference - March 5th, 2021
- Neuronetics Names Cory Anderson Vice President, Clinical Affairs and Medical Operations - March 3rd, 2021
- TCR² Therapeutics to Participate in Two Upcoming Conferences in March - March 3rd, 2021
- Market Report Bodes Well for Reflect Scientific Growth Potential - March 3rd, 2021
- Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81% - March 3rd, 2021
- Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating - March 3rd, 2021
- Longeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging Frailty - March 3rd, 2021
- Cognition Therapeutics to Present Corporate and Clinical Update at H.C. Wainwright Global Life Sciences Conference - March 3rd, 2021
- Arbor Biotechnologies Names Mark D. Angelino to its Board of Directors - March 3rd, 2021
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences - March 3rd, 2021
- Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference - March 3rd, 2021
- Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference - March 3rd, 2021
- Tricida Granted Additional U.S. Patent Covering Composition of Matter of Veverimer - March 3rd, 2021
- Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021 - March 3rd, 2021
- Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 - March 3rd, 2021
- Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference - March 3rd, 2021
- Notice to convene Annual General Meeting - March 3rd, 2021
- Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference - March 3rd, 2021
- Ceapro Inc. to Present at the H.C. Wainwright Global Life Sciences Conference - March 3rd, 2021
- 22nd Century Group Secures Exclusive Agreement with CannaMetrix to Accelerate Commercialization of New, Disruptive Hemp/Cannabis Plant Lines and... - March 3rd, 2021
- SetPoint Medical CEO Murthy Simhambhatla Named to AIMBE College of Fellows - March 3rd, 2021
- EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19 - March 1st, 2021
- Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021 - March 1st, 2021
- MacroGenics to Participate in Upcoming Investor Conferences - March 1st, 2021
- Cronos Group Reports 2020 Fourth Quarter and Full-Year Results - March 1st, 2021
- GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis... - March 1st, 2021
- Golden Leaf Holdings Enters into Letter of Intent to Acquire Retail Chain - March 1st, 2021
- TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update - March 1st, 2021
- Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B... - March 1st, 2021
- Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® - March 1st, 2021
- SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results - March 1st, 2021
- Molecular Templates to Participate in Upcoming Virtual Investor Conferences - March 1st, 2021
- ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American... - March 1st, 2021
- electroCore Inc. Announces Exclusive Distribution Agreement with Medistar Following Regulatory Approval in Australia - March 1st, 2021
- BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce... - March 1st, 2021
- Annual financial report 2020 - March 1st, 2021
- Idorsia submits NDA for clazosentan to Japanese PMDA - March 1st, 2021
- Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial - March 1st, 2021
- Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China - March 1st, 2021
- Orphazyme appoints Christophe Bourdon as Chief Executive Officer - March 1st, 2021
- Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® - February 27th, 2021
- Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer - February 27th, 2021
- Albireo Spotlights Global Patient Communities on Rare Disease Day - February 27th, 2021
- Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan - February 27th, 2021
Recent Comments